PTC Therapeutics Inc Translarna Deep Dive Transcript
Ladies and gentlemen, thank you for standing by, and welcome to the PTC Therapeutics Translarna Deep Dive. (Operator Instructions) I would now like to hand the conference over to your speaker today, PTC, CEO, Stu Peltz. Please go ahead, sir.
Thank you for joining our Deep Dive series. Today, we're going to focus on Translarna ahead of the dystrophin data readout in the first quarter 2021. We're going to be talking about the totality of evidence to support treatment with a disease-modifying therapy and the regulatory cap and its commercialization. We're planning to hold -- continue to hold a series of Deep Dives in 2021, including one on Huntington's disease ahead of the healthy volunteers data in the first half of 2021 to help you understand what to expect. So I will not be making forward-looking statements. So please look at the SEC documents.
Let's go to Slide 3. PTC has been the pioneer in discovering, developing and commercializing DMD therapies throughout the world.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
